Evidence map›Paper›PMID 38566991›Full record

ArticleFrontiers in immunology2024

Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection.

Emilie Goguet, Cara H Olsen, William A Meyer, Sara Ansari, John H Powers, Tonia L Conner, Si'Ana A Coggins, Wei Wang, Richard Wang, Luca Illinik and 38 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The Seraph 100Antibodies (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 11 institutions in 1 country.

Emilie GoguetDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Cara H OlsenDepartment of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
William A MeyerQuest Diagnostics, Secaucus, NJ, United States.
Sara AnsariQuest Diagnostics, Secaucus, NJ, United States.
John H PowersClinical Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Tonia L ConnerDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Si'Ana A CogginsDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Wei WangDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Richard WangDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Luca IllinikThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Margaret Sanchez EdwardsThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Belinda M Jackson-ThompsonDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Monique Hollis-PerryClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, United States.
Gregory WangClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, United States.
Yolanda AlcortaClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, United States.
Mimi A WongClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, United States.
David SaundersTranslational Medicine Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Roshila MohammedThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Bolatito BalogunThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Priscilla KobiThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Lakeesha KoshThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Kimberly Bishop-LillyBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Regina Z CerBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Catherine E ArnoldBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Logan J VoegtlyBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Maren FitzpatrickBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Andrea E LuquetteBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Francisco MalagonBiological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, MD, United States.
Orlando OrtegaThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Edward ParmeleeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Julian DaviesThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Alyssa R LindroseDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Hannah Haines-HullDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Matthew S MoserDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Emily C SamuelsDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Marana S RekedalDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Elizabeth K GraydonDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Allison M W MalloyDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
David R TribbleInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Timothy H BurgessInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Wesley CampbellDivision of Infectious Diseases, Walter Reed National Military Medical Center, Bethesda, MD, United States.
Sara RobinsonDivision of Infectious Diseases, Walter Reed National Military Medical Center, Bethesda, MD, United States.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Robert J O'ConnellInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Carol D WeissDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Simon PollettThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Uniformed Services University of the Health Sciences · USHenry M. Jackson Foundation · USLeidos (United States) · USGeneral Dynamics (United States) · USQuest Diagnostics (United States) · USUnited States Food and Drug Administration · USWalter Reed National Military Medical Center · USCenter for Biologics Evaluation and Research · USDefense Threat Reduction Agency · USFrederick National Laboratory for Cancer Research · USNaval Medical Research Command · US

Funding

NIAID NIH HHS Y01 AI005072
6 · The paper itself

Abstract

Introduction: We sought to determine pre-infection correlates of protection against SARS-CoV-2 post-vaccine inzfections (PVI) acquired during the first Omicron wave in the United States. Methods: Serum and saliva samples from 176 vaccinated adults were collected from October to December of 2021, immediately before the Omicron wave, and assessed for SARS-CoV-2 Spike-specific IgG and IgA binding antibodies (bAb). Sera were also assessed for bAb using commercial assays, and for neutralization activity against several SARS-CoV-2 variants. PVI duration and severity, as well as risk and precautionary behaviors, were assessed by questionnaires. Results: Serum anti-Spike IgG levels assessed by research assay, neutralization titers against Omicron subvariants, and low home risk scores correlated with protection against PVIs after multivariable regression analysis. Commercial assays did not perform as well as research assay, likely due to their lower dynamic range. Discussion: In the 32 participants that developed PVI, anti-Spike IgG bAbs correlated with lower disease severity and shorter duration of illness.

Indexed as

COVID-19AdultAntibodies, ViralCOVID-19 VaccinesHumansImmunoglobulin GSARS-CoV-2Antibodies, ViralCOVID-19 VaccinesImmunoglobulin Gcorrelates of immunityCOVID-19respiratory infectionSARS-CoV-2vaccination

Identifiers

PMID38566991
PMCPMC10985347
OpenAlexW4392966249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.